关于CEP72 rs924607 TT基因型和长春碱类相关外周神经毒性的meta分析

目的 评价CEP72 rs924607 TT基因型对急性淋巴细胞白血病(ALL)患儿长春碱类药物相关外周神经毒性发生的影响.方法 在Pubmed、Embase、Cochrane、中国知网、万方、维普、中国生物医学文献数据库中检索"acute lymphoblastic leukemia","vincristine","...     

三氧化二砷联合维生素C治疗初发Ⅲ期多发性骨髓瘤临床疗效观察

目的评价三氧化二砷（As2O3）联合维生素C方案应用于初发Ⅲ期多发性骨髓瘤（MM）的疗效.方法94例MM患者,临床分期均属于Ⅲ期.选择不同方案（M2、VAD、As2O3＋维生素C）分组治疗、随访、评估疗效.MM疗效标准分为完全缓解（CR）、部分反应（PR）、微小反应（MR）、无改变（NC）、平台期.结果①在提高部分缓解率方面,As2O3＋维生素C组优于VAD组、M2组,部分缓解率分别为52.9%、25.0%、17.8%.②As2O3＋维生素C组的生存期较VAD组、M2组延长.结论As2O3＋维生素C方案治疗初发Ⅲ期MM的疗效显著,明显改善症状、提高缓解率及延长生存期.     

High-dose Vincristine Sulfate Liposome Injection (Marqibo) Is Not Associated With Clinically Meaningful Hematologic Toxicity

BackgroundVincristine sulfate liposome injection (VSLI) facilitates vincristine dose intensification and densification, is active in untreated and relapsed lymphoma, and has been approved in the United States for relapsed and refractory acute lymphoblastic leukemia. Cancer- and concomitant chemotherapy-related anemia, neutropenia, and thrombocytopenia in patients with hematologic malignancy have complicated the evaluation of hematologic toxicity related to new drugs.Patients and MethodsWe assessed the hematologic toxicity of VSLI 2.25 mg/m² administered every 14 (cohort 1) or 7 (cohort 2) days in 54 patients with metastatic uveal melanoma, a cancer not known to involve the bone marrow.ResultsCohort 2 received a greater median number of VSLI doses (6 vs. 4) within a shorter median period (5.7 vs. 8.7 weeks), resulting in a larger median cumulative exposure (22.6 vs. 17.7 mg) and near doubling of the median dose density (2.2 vs. 4.0 mg/wk) compared with cohort 1. Despite greater VSLI exposure and dose density, cohort 2 had a lower median decrease from baseline in the neutrophil count and a greater increase from baseline in the platelet count compared with cohort 1. Hematologic adverse events (AEs) were uncommon and mostly grade 1 or 2 in severity. No grade 4 hematologic AEs developed.ConclusionVSLI at its approved dose resulted in a low incidence of clinically meaningful hematologic toxicity. A near doubling of the median dose density did not have an identifiable effect on the reported incidence and severity of hematologic AEs. VSLI could be well suited for use combined with myelosuppresive drugs and for patients unable to tolerate peripheral blood cytopenia.     

Loss of singing ability caused by vincristine

Two patients who received vincristine therapy for lymphoma suffered marked impairment of ability to sing as a consequence of neurotoxicity. Slow recovery occurred on drug withdrawal.     

Dual agents loaded PLGA nanoparticles: Systematic study of particle size and drug entrapment efficiency

PLGA nanoparticles simultaneously loaded with vincristine sulfate (VCR) and quercetin (QC) were prepared via O/W emulsion solvent evaporation. Six independent processing parameters and PLGA characteristics were assessed systematically to enhance the incorporation of the dual agents with different properties (VCR and QC, hydrophilic and hydrophobic molecule, respectively) into PLGA nanoparticles and control particle size. Approaches investigated for the enhancement of drug entrapment efficiencies and the controlling of particle size included the influence of the molecular weight (MW) of PLGA and the lactide-to-glycolide (L:G) ratio of PLGA, PLGA concentration, PVA concentration, initial QC content, acetone-to-dichloromethane (A/D) volume ratio, aqueous phase pH and aqueous to organic phase (W/O) volume ratio. The nanoparticles produced by optimal formulation were submicron size (139.5+/-4.3 nm, n=3) with low polydispersity index (0.095+/-0.031, n=3). Nanoparticles observed by transmission electron microscopy (TEM) showed extremely spherical shape. The entrapment efficiencies determined by high performance liquid chromatography (HPLC) by ultracentrifuge method were 92.84+/-3.37% for VCR and 32.66+/-2.92% for QC (n=3). The drug loadings were 0.0037+/-0.0001% for VCR and 1.36+/-0.12% for QC (n=3).     

Vincristine treatment in steroid-dependent nephrotic syndrome

Treatment of children with steroid-dependent nephrotic syndrome (SDNS) continues to be a challenge when relapses recur after treatment with cyclophosphamide and side effects or non-compliance make steroids and cyclosporin unsatisfactory. We treated 12 patients with intravenous vincristine for SDNS in a regime of 1–1.5 mg/m² weekly for 4 weeks then monthly for 4 months. Four of the 5 patients in relapse when commencing vincristine remitted within 2 doses. Comparing relapse frequency in the 12 months before and after vincristine, there was a reduction from 4 to 1.5 (p=0.004) relapses per year. Median sustained remission was 5 months, but 1 frequently relapsing patient remains in remission 4 years after vincristine. Vincristine was also successfully used in 1 or 2 doses at weekly intervals for subsequent relapses in 5 patients. Side effects were minimal in most cases. Abdominal pain occurred in 2 patients who commenced vincristine at 1.5 mg/m², but resolved when continued at 1 mg/m². We felt vincristine had a role in a subset of children with challenging SDNS administered as 1 mg/m² weekly for 4 weeks then 1.5 mg/m² monthly for 4 months. Vincristine allowed steroid- and cyclosporin-sparing, contributed to long-term remission in some patients, and was especially valuable in children with poor compliance with oral medication. Many patients expressed a preference for a few doses of vincristine rather than a standard course of oral prednisolone or cyclosporin.     

ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model

ABT-594 ((R)-5-(2-azetidinylmethoxy)-2-chloropyridine) represents a novel class of broad-spectrum analgesics whose primary mechanism of action is activation of the neuronal nicotinic acetylcholine receptors. The present study characterized the effects of ABT-594 in a rat chemotherapy-induced neuropathic pain model, where it attenuated mechanical allodynia with an ED50 = 40 nmol/kg (i.p.). This anti-allodynic effect was not blocked by systemic (i.p.) pretreatment with naloxone but was blocked completely with mecamylamine. Pretreatment with chlorisondamine (0.2-5 micromol/kg, i.p.) only partially blocked the effects of ABT-594 at the higher doses tested. In contrast, central (i.c.v.) pretreatment with chlorisondamine completely blocked ABT-594's anti-allodynic effect. Taken together, the data demonstrate that ABT-594 has a potent anti-allodynic effect in the rat vincristine model and that, in addition to its strong central site of action, ABT-594's effects are partially mediated by peripheral nicotinic acetylcholine receptors in this animal model of chemotherapy-induced neuropathic pain.     

Experimental investigations on a sequential combination chemotherapy protocol

Summary This paper deals with experimental investigations concerning the composition of a cytostatic three-drug-protocol in diploid Ehrlich-Ascites-Tumor (EAT) cells in vivo at a far advanced stage of the disease. Hydroxyurea (HU) and vincristine (VCR) were used in very low doses to induce a modification of the growth pattern of tumor cells alike partial synchronization. Adriamycin (ADM) was selected as cytocidal drug during DNA synthesis of the partially synchronized cells. It was found that the sequential combination of HU and VCR (first HU and 12h thereafter VCR) caused the greatest alteration of growth pattern compared with other combination protocols. A further statistically significant increase of the degree of synchrony was observed after a second VCR administration—22 h after HU. By means of this protocol the EAT was subdivided into two proliferating subpopulations, a diploid and a tetraploid one. the tetraploid population resulted from surviving cells being not able to perform cytokinesis correctly, so that polynuclear cells and cells with a large single nucleus containing tetraploid DNA values were created. With respect to therapy, the administration of ADM at the time of DNA synthesis of the partially synchronized cells resulted in a statistically significant prolongation of the mean survival time and in 30% of cures of the animals. The dosage of ADM was 2.6 mg/kg, i.e., a nonlethal dose (50% of the LD₁₀). Other combinations, i.e., simultaneous or reversed sequential combinations, did not show any therapeutic improvement compared to single drug therapy of ADM.the present time visiting professorship at the Medical Clinic of the University of CologneSupported by Deutsche Forschungsgemeinschaft     

Retinal changes induced by treatment with vincristine and vinblastine

The mitosis-inhibiting Vinca-alkaloids vincristine sulphate and vinblastine sulphate were injected into the vitreous body. This treatment resulted in ultrastructural changes in the retina within an hour. The retinal nerve cells showed a marked increase in the number of cell organelles, including the 100 Å filaments found in their perikarya. The microtubules disappeared and crystalloid structures appeared within an hour. The axons became distended by accumulated cell organelles, usually surrounding a crystalloid. The synaptic bodies, especially the presynaptic ones, often contained crystalloids, and showed a transient increase in the number of synaptic vesicles. The inner segments of the photoreceptor cells showed similar ultrastructural alterations, and, in addition, stacks of membranous structures. The outer segments decreased in length, and only rudiments of these structures remained one week after the intravitreal injection. The non-pigmented epithelial cells and the Müller's neuroglial cells also showed marked structural alterations.These ultrastructural changes are consistent with the biochemical and fluorescence microscopic observations that vincristine and vinblastine both inhibit the intracellular flow of cell constituents, as previously demonstrated to be the case with colchicine. It is proposed that the structural changes in the individual cells reflect the drug-induced imbalance between the inhibited intracellular transport and the continued formation of the cell constituents characteristic of the afflicted cell.This study was supported by grants from M. Bergwalls Stiftelse, W. and M. Lundgrens Stiftelse, H. Hiertas Stiftelse, Swedish Medical Research Council (B 72-12 X-2543-04 A) and the Swedish National Cancer Society (265 - B 70-02 X).     

肝癌细胞自噬性凋亡过程中caspase-3基因的克隆与鉴定

目的从长春新碱诱导发生自噬性凋亡的肝癌细胞系HepG2中克隆caspase-3基因。方法提取细胞总RNA,采用RT-PCR技术扩增目的片段,构建重组克隆载体,测序鉴定及分析。结果经RT-PCR获得了预期的扩增产物即caspase-3基因625bp的核苷酸片段,其测序结果与文献报道一致。结论初步证明该caspase-3基因片段参与了长春新碱诱导的HepG2细胞自噬性凋亡过程。